Dragon Copilot is architected on a highly secure, scalable, and healthcare-specific foundation that merges advanced natural language processing, ambient listening technology, and generative AI capabilities. These sophisticated technologies enable seamless documentation by capturing physician-patient interactions in real time, directly integrating comprehensive clinical notes into the electronic health record (EHR) system. By automating cumbersome administrative duties and surfacing critical clinical data instantaneously, Dragon Copilot facilitates a smoother, more efficient clinical workflow and drastically reduces the time clinicians spend on paperwork.

Lisa Stump, Executive Vice President and Chief Digital Information Officer at Mount Sinai Health System, emphasized that after a rigorous multi-vendor evaluation, this deployment of Dragon Copilot signifies a transformative leap in technological support for clinicians. The AI assistant is directly embedded within the clinical workflow, effectively alleviating the pervasive issue of documentation fatigue while enhancing information flow. This, in turn, frees healthcare providers to dedicate more time and attention to patient care—ultimately advancing Mount Sinai’s mission of delivering exceptional health services.

The underlying technology employs unified voice recognition and ambient listening, allowing caregivers—including physicians and nurses—to document care through natural, conversational dialogue during clinical encounters. These capabilities are augmented by generative AI, which synthesizes and organizes the documented information, simplifying intricate clinical tasks and improving care coordination. This results in higher documentation accuracy and speed, fostering richer interactions with patients who benefit from more attentive and engaged providers.

Brendan G. Carr, MD, MA, MS, CEO of Mount Sinai Health System, articulated the institution’s responsible approach to AI integration, underscoring that Dragon Copilot is intended not to supplant human clinical judgment but to empower it. The AI acts as an extension of the care team, enhancing human decision-making by providing timely, contextual information and streamlining workflows. This partnership between human expertise and artificial intelligence is designed to facilitate smarter, more interconnected, and compassionate care delivery.

Kenneth Harper, General Manager of the Dragon product for Microsoft Health and Life Sciences, acknowledged Mount Sinai’s leadership in academic medicine innovation. He highlighted that embedding ambient and generative AI directly into clinical processes helps reduce clinician burnout and reclaim valuable time, enabling healthcare professionals to reconnect with their patients meaningfully. This deployment exemplifies a shared vision of responsible AI use that centers the human element within the healthcare experience.

The phased rollout of Dragon Copilot has commenced with select departments at Mount Sinai, with plans for a comprehensive system-wide implementation scheduled for 2026. Each stage includes meticulous training programs, ongoing feedback mechanisms, and detailed evaluations to ensure a secure, equitable, and effective integration. This careful, iterative approach helps safeguard both clinician satisfaction and patient safety while optimizing AI tool adoption.

Mount Sinai’s commitment to AI-driven innovation is part of a broader digital strategy aimed at enhancing clinician well-being, operational efficiency, and clinical outcomes. By adopting sophisticated AI companions like Dragon Copilot, the health system reinforces its status as a national exemplar of innovation in academic medicine, poised to transform healthcare delivery on multiple fronts.

In deploying Dragon Copilot, Mount Sinai not only reduces the cognitive burden associated with exhaustive documentation but also addresses clinician burnout—a critical concern in modern healthcare environments. The ambient AI listens passively in the background, capturing clinical narratives without disrupting the natural physician-patient dialogue. This ambient data collection is then processed by advanced generative models that produce accurate, comprehensive clinical notes and prompt necessary administrative actions, facilitating better clinician focus and improved care continuity.

Furthermore, the integration of AI-driven clinical documentation significantly enhances data interoperability and information retrieval within the EHR. The system’s capability to distill and elevate the most pertinent clinical facts ensures that providers have ready access to critical patient insight, supporting informed decision-making and enabling personalized care plans grounded in comprehensive, up-to-date information.

Mount Sinai Health System’s expansive infrastructure, consisting of seven hospitals, hundreds of outpatient practices, and numerous research centers, provides a demanding environment that benefits profoundly from such AI-enabled transformation. The scale and complexity of its clinical operations underscore the necessity for innovative solutions that can reduce the administrative burden on healthcare workers and streamline patient management across diverse care settings.

The integration of Dragon Copilot at Mount Sinai serves as a beacon for the broader medical community, showcasing how AI can be ethically and effectively harnessed to augment clinical practice. As healthcare continues to grapple with increasing data volumes, regulatory pressures, and workforce challenges, such AI assistants offer vital tools to sustain high-quality care delivery and promote clinician resilience.

For those interested in following Mount Sinai’s ongoing AI advancements, the institution maintains a dedicated resource hub, chronicling their progress in embedding artificial intelligence into healthcare systems. This provides a wealth of information about how cutting-edge AI technologies like Dragon Copilot are reshaping academic medicine and clinical care on a broader scale.

Subject of Research: Artificial Intelligence in Clinical Documentation and Workflow Automation
Article Title: Mount Sinai Health System Partners with Microsoft to Deploy AI-Powered Dragon Copilot Clinical Assistant
News Publication Date: Not explicitly provided in the text
Web References: https://icahn.mssm.edu/about/artificial-intelligence; https://www.mountsinai.org
Keywords: Artificial Intelligence, Clinical Documentation, Electronic Health Record, Generative AI, Ambient Listening, Healthcare Innovation, Clinical Workflow Automation, Digital Transformation, Clinician Burnout, Patient Care, Academic Medicine, AI in Healthcare

This collaboration also extends to the U.S. teams in the Billie Jean King Cup and Davis Cup, marking Mount Sinai’s 11th year serving as their trusted medical partner. Across these high-performance tournaments, Mount Sinai has consistently integrated clinical excellence with the demands of elite athletic performance, underscoring the seamless fusion of academic medical innovation and real-time sports patient care.

Orthopedics and sports medicine lie at the heart of this partnership, addressing the acute injuries, chronic conditions, and rehabilitation needs inherent in professional tennis. Mount Sinai’s onsite services are staffed by a cadre of renowned specialists, including Professor Alexis Colvin, MD, Chief Medical Officer of the US Open and U.S. Billie Jean King Cup Team Physician. Dr. Colvin’s unique expertise in sports-related musculoskeletal injuries and her pioneering leadership reflect the institution’s commitment to athlete-centered care. She is joined by notable colleagues such as Dr. Melissa Leber, Associate Professor of Orthopedics and Emergency Medicine and Director of Player Medical Services, who brings a sophisticated blend of emergency medicine and sports science to the daily management of player health.

Behind the scenes, the Department of Diagnostic, Molecular, and Interventional Radiology provides state-of-the-art imaging support critical to rapid diagnosis and treatment planning. Utilizing portable, laptop-sized ultrasound machines equipped with specialized musculoskeletal probes, the radiology team, led by Dr. Jhanna Moore, can perform detailed assessments of soft tissue and joint injuries. This diagnostic agility enables immediate triage and tailored clinical decisions in a high-pressure tournament setting, often distinguishing between minor strains manageable onsite and injuries warranting advanced imaging and intervention at The Mount Sinai Hospital.

Mount Sinai’s continuous innovation in medical technology integration is exemplified by its deployment of the LOGIQ e ultrasound system during the US Open. This device’s portability and precision facilitate onsite diagnostic ultrasounds, affording clinicians the ability to perform ultrasound-guided injections, aspirations, and dynamic musculoskeletal evaluations. Such techniques underscore the paradigm shift in sports medicine—from reactive treatment towards proactive management and minimally invasive intervention, aiming to expedite athlete recovery while minimizing downtime.

Emergency medicine specialists at Mount Sinai complement this orthopedic expertise by providing rapid, comprehensive care for acute trauma, ensuring that any sudden injury—ranging from concussions to heat-related illnesses—is met with swift, evidence-based response protocols. Dr. Melissa Leber, a dual board-certified expert in emergency and sports medicine, leverages her extensive experience across professional sports leagues, such as the NBA and NFL, to refine sideline care and injury prevention strategies unique to the biomechanics and competitive stresses of tennis.

The holistic approach further extends into musculoskeletal radiology, acupuncture, dermatology, and podiatry services, all accessible onsite to address the multifactorial nature of athlete health. Mount Sinai also offers an onsite pharmacy and blood draw services to streamline treatment and diagnostics. Mental health support, although provided remotely, integrates psychological resilience and wellness into the broader care continuum, recognizing the intense mental demands placed on professional athletes competing at the highest levels.

Leading orthopedic surgeon and Mount Sinai Professor Leesa M. Galatz, MD, affirms that key improvements in treatment programs each year reflect Mount Sinai’s dedication to marrying clinical research advancements with practical applications. The longitudinal relationship with the USTA allows the hospital to pioneer customized interventions, including regenerative medicine techniques and refined rehabilitation protocols, that reflect the evolving landscape of sports medicine and athletes’ endurance.

Mount Sinai’s involvement also embraces community and fan engagement through interactive onsite experiences, reinforcing the institution’s mission of “Serving All.” Fans can participate in innovative activities such as creating artificial intelligence-driven tennis avatars, bridging technology and sports culture in novel ways. In addition, the hospital facilitates player meet-and-greet sessions and visibility during matches, fostering closer connections between fans and medical experts dedicated to athlete care.

More broadly, this partnership exemplifies how academic medical centers enable elite sports competitions to achieve unprecedented levels of safety, performance optimization, and injury prevention. By integrating research, clinical practice, and technology deployment—backed by a robust team of 20+ faculty members across departments—Mount Sinai ensures that athletes at the US Open have access to comprehensive diagnostics and therapeutics in real time.

Structural innovations in diagnostic imaging, such as seamless remote MRI image reviews and rapid ultrasound diagnostics, position Mount Sinai as a leader in elevating the standard of onsite sports medicine. The collaboration also highlights the critical interface between acute medical care and long-term athlete health, underscoring the importance of multidisciplinary approaches combining surgical expertise, emergency medicine, rehabilitative care, and radiology.

Behind these efforts is a resolute commitment to gender equity and female representation within sports medicine leadership. Dr. Colvin emphasizes the inspirational nature of tennis as a sport where female athletes maintain equal prominence and prize money, which enriches the medical care providers’ mission to support athletes across genders and generations, including young powerful players and mothers competing at elite levels.

As a premier academic health system, Mount Sinai continues to advance health outcomes for athletes by embracing the complexity of musculoskeletal science, precision medicine, and collaborative care models. The institution’s work at the US Open serves as a microcosm of its broader pursuit of medical excellence—improving quality of life through innovative techniques, patient-focused care strategies, and fostering wellbeing through all stages of athletic participation.

With extensive experience managing athlete health through diverse specialties and a commitment to cutting-edge clinical integration, Mount Sinai’s continued role at the 2025 US Open showcases a blueprint for excellence in sports medicine. This partnership not only supports the present generation of tennis champions but also drives forward the science and art of athlete care, setting new benchmarks for comprehensive, rapid-response, and highly specialized treatment environments in professional sports.

Subject of Research: Sports Medicine, Musculoskeletal Radiology, Orthopedics, Emergency Medicine in Elite Tennis Competitions

Article Title: Mount Sinai Elevates Onsite Sports Medicine at the 2025 US Open: A Technological and Clinical Evolution

News Publication Date: August 15, 2025

Web References:

• https://profiles.mountsinai.org/alexis-c-colvin
• https://profiles.mountsinai.org/melissa-d-leber
• https://profiles.mountsinai.org/james-n-gladstone
• https://www.facebook.com/mountsinainyc
• https://www.instagram.com/mountsinainyc
• https://www.linkedin.com/company/mountsinainyc/
• https://twitter.com/mountsinainyc
• https://www.youtube.com/mountsinainy

Keywords: Sports medicine, Orthopedics, Musculoskeletal radiology, Emergency medicine, Ultrasound diagnostics, Tennis injuries, Athlete care, US Open, Medical technology, Multidisciplinary medicine

The System for Change Award, one of the three accolades received, distinguishes health systems that have exhibited substantial leadership and commitment to embedding sustainability deeply within their organizational culture and daily operations. Out of nearly 400 hospital systems nationwide, Mount Sinai stands as one of a select group of 15 honored for this milestone. This award is not simply a badge of recognition but a reflection of the systemic transformation occurring at Mount Sinai, where sustainability principles are ingrained at all levels, from administrative practices to clinical protocols.

In parallel, several of Mount Sinai’s campuses were recognized with the Emerald Award, reserved for hospitals showcasing exceptional, advanced sustainability programs paired with tangible environmental performance outcomes. This accolade was conferred upon The Mount Sinai Hospital, Mount Sinai West, and Mount Sinai Brooklyn for their exemplary initiatives. These hospitals have implemented cutting-edge strategies that not only reduce their carbon footprint but also create healthier, more sustainable environments for patients, staff, and the surrounding communities.

The Partner for Change Award further highlights specific campuses within the Mount Sinai network exhibiting superior performance in environmental sustainability. Mount Sinai Morningside, Mount Sinai Queens, and the New York Eye and Ear Infirmary each received this honor for their commitment to continuous improvement in sustainability metrics. These distinctions collectively portray a health system-wide culture of innovation and responsibility toward ecological impact reduction.

Mount Sinai Green initiatives encompass a broad array of environmental priorities. Central to these efforts are waste reduction programs designed to minimize landfill contributions through comprehensive recycling and repurposing protocols. Simultaneously, energy efficiency programs leverage data-driven technologies to optimize resource use, including the integration of waste heat recovery systems in data centers—a pioneering step in reducing overall energy consumption and greenhouse gas emissions. These technical implementations showcase Mount Sinai’s investment in scalable, innovative solutions that marry operational efficiency with environmental goals.

The synergy between Mount Sinai’s sustainability agenda and its scientific research is notable. Scientists at the Icahn School of Medicine at Mount Sinai are actively investigating the intricate relationships between environmental exposures and human health outcomes. This research informs clinical and organizational practices that prioritize environmental determinants of disease, underscoring the interconnectedness of planetary health and patient care. By aligning sustainability with cutting-edge biomedical research, Mount Sinai sets a model for evidence-based environmental stewardship in healthcare.

Leadership voices at Mount Sinai emphasize that environmental responsibility transcends regulatory compliance—it is intrinsic to delivering high-quality patient care. The Medical Director of Sustainability, Dr. Muoi A. Trinh, articulates a vision where safer and healthier environments promote healing while reducing risks associated with environmental hazards. This philosophy guides new sustainability initiatives aimed at enhancing indoor air quality, reducing harmful emissions, and implementing greener procurement policies.

Mount Sinai’s executive leadership is also propelling the system forward by committing to ambitious climate targets. Signing the New York State Insurance Fund Climate Action Pledge, the health system is dedicated to halving its emissions by 2030 and achieving net-zero status by 2050. This strategic framework encompasses not only emission reductions but also bolstering campus resilience to climate impacts, a crucial consideration given the increasing frequency of extreme weather events that threaten healthcare infrastructure.

Future efforts will include a refined supplier engagement program, in which carbon emissions embedded in the supply chain will be rigorously tracked and scored. The emphasis on addressing upstream environmental impacts represents a sophisticated understanding that healthcare sustainability must extend beyond direct facility operations to encompass the full lifecycle of medical products and pharmaceuticals. Particularly innovative is Mount Sinai’s intention to promote the use of lower carbon medications, a frontier in sustainable clinical pharmacology.

Technology-driven solutions remain a cornerstone of Mount Sinai’s approach. The innovative application of waste heat recovery systems—capturing and reutilizing thermal energy generated by data center operations—is an example of the hospital’s commitment to integrating advanced engineering solutions for environmental gains. These cutting-edge technologies not only reduce operational costs but also position Mount Sinai as a leader in sustainable healthcare infrastructure design.

Moreover, Mount Sinai Health System actively participates in collaborative networks, such as Practice Greenhealth, which provide platforms for sharing best practices and benchmarking sustainability progress. This membership facilitates ongoing learning and leadership within the healthcare sector’s climate action movement, further amplifying the impact of Mount Sinai’s initiatives on a national scale.

The comprehensive sustainability strategy Mount Sinai pursues resonates beyond environmental benefits; it directly interfaces with equitable health outcomes. By fostering greener, healthier hospital environments and communities, the institution champions a model where ecological and social determinants of health converge, driving improved wellness and resilience for vulnerable populations.

Ultimately, Mount Sinai’s environmental achievements signify an essential evolution in healthcare philosophy—a shift toward embracing ecological responsibility as a foundational element of medical excellence and public health advocacy. As climate change continues to pose unprecedented challenges, Mount Sinai exemplifies how healthcare systems can lead transformative change, not only healing patients but also healing the planet.

Subject of Research: Environmental sustainability and climate action initiatives in healthcare systems

Article Title: Mount Sinai Health System Sets National Benchmark with Triumphant Environmental Excellence Awards

News Publication Date: June 9, 2025

Web References:

• Mount Sinai Facebook
• Mount Sinai Instagram
• Mount Sinai LinkedIn
• Mount Sinai Twitter (X)
• Mount Sinai YouTube

Keywords: Environmental issues, Sustainability, Greenhouse gases, Climate change, Environmental impact assessments, Environmental policy

Dr. Charney’s research contributions have been pivotal in advancing our understanding of complex psychiatric disorders. As a neurobiologist specializing in the molecular bases of anxiety, fear, depression, and resilience, his work has yielded groundbreaking insights that have directly informed the development of novel therapeutic interventions. Notably, Dr. Charney was recognized as one of the 2025 TIME 100 Health Most Influential People in Health, a testament to his innovative approach and success in creating breakthrough treatments for depression. His research into the neurochemical pathways involved in mood regulation has helped usher in new pharmacological agents that offer hope to millions suffering from mental health conditions.

Under Dr. Charney’s visionary leadership, the Icahn School of Medicine embarked on a profound journey of expansion and scientific discovery. He actively cultivated a multidisciplinary environment by recruiting top-tier faculty across various fields such as biomedical sciences, computational biology, and information technology. This convergence of disciplines fostered an ecosystem of scientific risk-taking and resource sharing that challenged conventional boundaries within academic medicine. The school’s commitment to interdisciplinary collaboration led to the establishment of over two dozen research institutes dedicated to cutting-edge investigations in cancer, cardiovascular diseases, gastrointestinal disorders, and psychiatric illnesses, highlighting the school’s broad impact in multiple medical domains.

A defining hallmark of Dr. Charney’s tenure was the dramatic increase in funding from the National Institutes of Health (NIH), which soared to an unprecedented $500 million annually by 2024. This influx situates the Icahn School of Medicine at Mount Sinai as the 11th highest recipient of NIH funding among all U.S. medical schools and places it in the 99th percentile for research funding among private institutions. This financial support has empowered the school to advance its research infrastructure, recruit leading scientists, and train the next generation of medical innovators. Moreover, the expansion of the graduate medical education program under Dr. Charney’s leadership created the largest residency and clinical fellowship cohort in the nation, now exceeding 2,600 trainees.

Dr. Charney also forged strategic partnerships with technological and academic powerhouses such as the Hasso Plattner Institute, Rensselaer Polytechnic Institute, and the State University of New York at Stony Brook. These collaborations have been instrumental in developing digital health tools that advance precision medicine—a rapidly emerging field that leverages data analytics, machine learning, and personalized biological insights to optimize patient care. One historic advancement co-invented by Dr. Charney is ketamine, an FDA-approved rapid-acting antidepressant marketed as SPRAVATO™. Ketamine’s novel mechanism of action has revolutionized treatment paradigms for resistant depression, offering patients fast and effective relief where traditional antidepressants often fail.

In addition to pharmacological innovations, Dr. Charney is a pioneer in the digital therapeutics space, having co-developed Rejoyn, the first FDA-approved prescription digital therapeutic for major depressive disorder (MDD). This technology employs computer-guided behavioral therapy and data-driven patient engagement strategies that complement traditional medical treatments. Such digital interventions epitomize the future of mental health care, blending psychological science with software engineering to expand accessibility and efficacy. Dr. Charney’s dual achievement in both chemical and digital therapeutics exemplifies his comprehensive and forward-thinking approach to mental health research and treatment.

His scientific excellence has been recognized through numerous prestigious awards, cementing his status as a leader in psychiatric research. Dr. Charney was inducted into the National Academy of Medicine in 2000, a distinction reserved for individuals who have made profound contributions to medical science. His accolades include the Colvin Prize for Outstanding Achievement in Mood Disorder Research awarded in 2019 and the Rhoda & Bernard Sarnat International Prize in Mental Health from the National Academy of Medicine in 2023. These honors highlight his sustained commitment to understanding and addressing the biological underpinnings of mental illness.

The Mount Sinai Health System leadership has lauded Dr. Charney’s transformational impact on the school and health system. Brendan G. Carr, MD, and Kenneth L. Davis, MD, praised his ability to assemble a world-class team and secure the necessary resources that will sustain the school’s trajectory of excellence. They emphasized his unique leadership qualities that blend innovative thinking with steadfast dedication. Similarly, Kenneth L. Davis reflected on Dr. Charney’s “outside-the-box” leadership style, which defied traditional constraints and forged a culture strong enough to elevate the Icahn School of Medicine into a premier institution for biomedical education and research.

Echoing this sentiment, Richard A. Friedman and James S. Tisch, Co-Chairs of the Mount Sinai Health System Boards of Trustees, referred to Dr. Charney as a visionary transformative leader who successfully implanted an entrepreneurial spirit within the school. By fostering an environment conducive to innovation and risk-taking, Dr. Charney created a dynamic academic culture that continues to push the boundaries of biomedical research and patient care. His strategic direction is seen as a cornerstone of the institution’s success and future potential.

In the wake of this leadership transition, Eric J. Nestler, MD, PhD, has been appointed as Interim Dean of the Icahn School of Medicine. Dr. Nestler is a distinguished molecular neuroscientist known for his work on the mechanisms underlying addiction and depression. He has served as Dean for Academic Affairs since 2016 and as Chief Scientific Officer of the Mount Sinai Health System, with a prolific publication record of over 750 papers and five books. His election to the National Academy of Sciences—the highest honor for original scientific research—underscores his stature in the biomedical community and promises continuity in the school’s scientific mission.

Mount Sinai Health System itself stands as a pillar of comprehensive care and biomedical innovation in the New York metropolitan area. Employing 48,000 staff across seven hospitals, over 400 outpatient practices, and more than 600 research and clinical laboratories, it is among the largest academic medical systems in the region. The Health System’s integrated model combines cutting-edge scientific research, education, and clinical care to address complex health challenges using novel technologies including artificial intelligence and informatics. Its hospitals routinely receive accolades from Newsweek and U.S. News & World Report, reflecting their excellence in healthcare delivery.

The Icahn School of Medicine’s ever-expanding research footprint and educational programs have played an essential role within this ecosystem. Taking advantage of state-of-the-art facilities and a comprehensive network of healthcare providers, faculty and students are uniquely positioned to translate scientific discoveries into tangible health improvements. The synergy between research and clinical enterprises fuels innovations that continue to broaden treatment options for a wide spectrum of diseases, from cancer and heart disease to psychiatric and gastrointestinal disorders.

Looking ahead, the Icahn School of Medicine at Mount Sinai is poised to build on the foundation laid by Dr. Charney’s leadership. The school’s emphasis on cross-disciplinary collaboration, augmented by strategic partnerships and cutting-edge digital health innovations, positions it as a global leader ready to tackle the evolving challenges of medicine. As Dr. Nestler steps into his interim role, the institution’s vibrant culture of research excellence and education stands insured, ensuring that the next generation of physicians and scientists will carry the torch forward.

Subject of Research: Neurobiology of mood disorders, mechanisms of depression and anxiety, development of novel pharmacological and digital therapeutics.

Article Title: Not explicitly provided in the source content.

News Publication Date: May 13, 2025

Web References:
https://time.com/collections/time100-health-2025/7279649/dennis-charney/

Keywords: Health and medicine, neurobiology, depression, anxiety, resilience, ketamine, SPRAVATO™, digital therapeutics, Rejoyn, biomedical innovation, academic medicine, precision medicine.